Last reviewed · How we verify
LY2605541
LY2605541 is a long-acting basal insulin analog that binds to the insulin receptor to lower blood glucose levels in diabetes.
LY2605541 is a long-acting basal insulin analog that binds to the insulin receptor to lower blood glucose levels in diabetes. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.
At a glance
| Generic name | LY2605541 |
|---|---|
| Also known as | Insulin Peglispro, Insulin peglispro |
| Sponsor | Eli Lilly and Company |
| Drug class | Basal insulin analog |
| Target | Insulin receptor |
| Modality | Biologic |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
LY2605541 is a modified human insulin designed to have an extended duration of action, allowing for less frequent dosing compared to standard insulin formulations. It works by activating insulin receptors on target tissues, promoting glucose uptake and utilization while suppressing hepatic glucose production. The structural modifications enable sustained absorption and prolonged pharmacodynamic activity.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Injection site reactions
- Weight gain
Key clinical trials
- A Study to Compare the Effect of a Double Dose of Two Long-acting Insulin Therapies in Participants With Type 2 Diabetes (PHASE3)
- A Study of LY2605541 and Glargine in Participants With Type 1 Diabetes (PHASE1)
- A Study of LY3192767 in Healthy Participants (PHASE1)
- A Study Comparing Insulin Peglispro With Insulin Glargine as Basal Insulin Treatment (PHASE3)
- A Study of LY2605541 and Glargine and Exercise in Participants With Type 1 Diabetes (PHASE1)
- A Study of Insulin Peglispro and Glargine on Fats in Participants With Type 1 Diabetes (PHASE1)
- A Study of LY2605541 Versus Insulin Glargine on Blood Sugar (PHASE1)
- A Study of LY2605541 (Insulin Peglispro) and Human Insulin Concentrations in Fat Tissue (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LY2605541 CI brief — competitive landscape report
- LY2605541 updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI